MLSS · XBRL financial data

Milestone Scientific financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MLSS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cost of goods and services sold	556	750*	573	443	678	502*	585	706	719	556*	598	931
Gross profit	1,503	—	1,676	1,411	1,836	—	1,647	1,618	1,641	—	1,564	1,910
Research and development	170	177*	94	315	232	218*	369	52	16	12*	—	7
Selling, general and administrative	2,824	3,301*	3,035	2,868	3,065	3,327*	3,257	3,031	2,739	2,550*	2,373	2,946
Total operating expenses	3,010	3,490*	3,141	3,192	3,305	3,553*	3,645	3,102	2,775	2,581*	2,392	2,972
Operating income (loss)	(1,507)	(1,980)*	(1,465)	(1,780)	(1,469)	(2,042)*	(1,998)	(1,485)	(1,134)	(1,080)*	(828)	(1,062)
Income tax expense (benefit)	0	0*	0	0	—	—	—	0	—	—	—	—
Net income (loss)	(1,466)	(1,939)*	(1,441)	224	(1,461)	(2,036)*	(1,995)	(1,483)	(1,154)	(1,091)*	(840)	(1,059)
Earnings per share, basic USD per share	(0.02)	(0.03)*	(0.02)	0.00	(0.02)	(0.03)*	(0.02)	(0.02)	(0.01)	(0.01)*	(0.01)	(0.01)
Earnings per share, diluted USD per share	—	—	—	—	(0.02)	—	(0.02)	(0.02)	(0.01)	(0.01)*	(0.01)	(0.01)
Weighted average shares, basic thousands of shares	73,731	72,915*	79,739	79,967	79,967	79,494*	81,855	82,050	82,323	82,024*	85,042	93,126
Weighted average shares, diluted thousands of shares	—	—	—	79,967	79,967	—	81,855	82,050	82,323	82,024*	85,042	93,126

Balance sheet

CSV

Fiscal quarters (MLSS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	2,171	2,978	4,005	5,752	4,776	3,258	2,246	1,274	1,345	1,113	1,200	2,067
Marketable securities	2,450	2,977	1,000	0	0	0	—	—	—	—	—	—
Accounts receivable	591	313	662	387	551	475	—	—	—	—	—	—
Inventory	2,483	2,638	2,860	3,329	3,712	3,713	4,159	3,897	4,127	3,782	3,492	3,087
Prepaid and other current assets	579	518	864	775	646	565	750	638	507	469	677	634
Total current assets	9,973	10,794	10,812	11,494	10,699	9,287	8,625	7,631	8,110	7,478	7,353	8,117
Property and equipment, net	9	10	8	13	11	13	12	15	18	19	18	20
Right-of-use asset	378	355	331	308	283	258	232	214	178	150	122	92
Total assets	10,584	11,372	11,351	12,005	11,175	9,797	9,088	8,051	8,486	7,806	7,963	8,348
Accrued liabilities	1,112	1,512	1,241	1,070	1,268	1,796	1,316	1,389	—	—	—	—
Total current liabilities	3,279	3,077	3,637	3,826	3,758	3,744	4,444	3,768	5,034	4,131	4,858	4,397
Lease liability, non-current	309	282	254	225	196	166	134	102	69	35	—	—
Total liabilities	3,591	3,359	3,890	4,051	3,953	3,964	4,626	4,711	5,937	4,994	5,678	4,877
Accumulated deficit	(121,401)	(123,340)	(124,780)	(124,556)	(126,018)	(128,053)	(130,048)	(131,531)	(132,685)	(133,775)	(134,615)	(135,675)
Total stockholders' equity	7,246	8,013	7,460	7,954	7,221	5,833	4,462	3,340	2,549	2,813	2,285	3,471
Total liabilities and equity	10,584	11,372	11,351	12,005	11,175	9,797	9,088	8,051	8,486	7,806	7,963	8,348
Common shares outstanding (cover page) thousands of shares	71,048	76,602	77,228	77,288	77,892	78,380	78,477	78,559	78,629	80,453	88,075	88,739

Cash flows

CSV

Fiscal quarters (MLSS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,466)	(1,939)*	(1,441)	224	(1,461)	(2,036)*	(1,995)	(1,483)	(1,154)	(1,091)*	(840)	(1,059)
Stock-based compensation	320*	354*	314	208*	484*	340*	331	160*	363*	99*	257	310*
Depreciation and amortization	16	12*	12	8	9	—	—	—	—	—	—	—
Net cash from operating activities	(1,053)*	(1,246)*	(1,218)	784*	(974)*	(1,511)*	(1,008)	(1,764)*	82*	(226)*	87	(585)*
Purchases of property and equipment	—	—	—	—	—	4*	1	4*	6*	3*	2	4*
Net cash from investing activities	(475)*	(514)*	2,004	966*	0*	(4)*	(1)	(4)*	(6)*	(3)*	(2)	(4)*
Proceeds from issuing common stock	—	year only	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	(2)*	2,567*	241	(3)*	(3)*	(3)*	(2)	797*	(5)*	(3)*	(3)	1,462*
Net change in cash	(1,531)*	807*	1,028	1,747*	(977)*	(1,518)*	(1,012)	(972)*	71*	(233)*	82	872*

Compare with peers

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Vicarious Surgical	1,407	not reported	(6,325)	not reported	0.6 quarters	Q1 FY26 10-QMar 31, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Modular Medical	3,920	not reported	(5,972)	8.2M	0.7 quarters	Q1 FY27 10-QJun 30, 2026
HeartBeam	8,722	not reported	(3,342)*	56.3M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.